Kala Pharmaceuticals Q1 2024 Adj EPS $(4.20) Misses $(2.89) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kala Pharmaceuticals reported a Q1 2024 adjusted EPS loss of $(4.20), missing the consensus estimate of $(2.89) by 45.33%.
May 14, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kala Pharmaceuticals reported a significant miss in its Q1 2024 earnings, with losses per share of $(4.20) versus the expected $(2.89).
Earnings misses typically lead to negative investor sentiment and can cause a short-term decline in stock price. The significant miss reported by Kala Pharmaceuticals is likely to result in decreased confidence from investors and analysts, potentially leading to a decrease in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100